These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 20334824)

  • 1. [Can the nephroprotective effect of N-acetylcysteine be optimized?].
    Barrios V; Escobar C; Echarri R
    Rev Esp Cardiol; 2010 Apr; 63(4):501-2. PubMed ID: 20334824
    [No Abstract]   [Full Text] [Related]  

  • 2. Review of contrast-induced nephropathy and current use of N-acetylcysteine (NAC).
    Anwar M; Ledger S
    CANNT J; 2005; 15(1):33-8,quiz 38-9. PubMed ID: 15909775
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevention of contrast-induced renal dysfunction by N-acetylcysteine. Truth or myth?
    Billinger M; Hess OM; Meier B
    Eur Heart J; 2004 Feb; 25(3):188-9. PubMed ID: 14972417
    [No Abstract]   [Full Text] [Related]  

  • 4. Sodium bicarbonate, N-acetylcysteine, and saline for the prevention of contrast-induced nephropathy.
    Bouzas-Mosquera A; Recio-Mayoral A
    Am Heart J; 2008 Apr; 155(4):e31. PubMed ID: 18371455
    [No Abstract]   [Full Text] [Related]  

  • 5. [The use of acetylcysteine for preventing contrast-induced nephropathy].
    Schaad N; Barghouth G
    Rev Med Suisse; 2005 Jun; 1(25):1693-6. PubMed ID: 16117036
    [No Abstract]   [Full Text] [Related]  

  • 6. N-acetylcysteine and contrast-induced nephropathy.
    Ritz E
    N Engl J Med; 2006 Oct; 355(14):1499; author reply 1499-500. PubMed ID: 17024738
    [No Abstract]   [Full Text] [Related]  

  • 7. N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials.
    Stenstrom DA; Muldoon LL; Armijo-Medina H; Watnick S; Doolittle ND; Kaufman JA; Peterson DR; Bubalo J; Neuwelt EA
    J Vasc Interv Radiol; 2008 Mar; 19(3):309-18. PubMed ID: 18295688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing nephropathy induced by contrast medium.
    Tepel M
    N Engl J Med; 2006 Apr; 354(17):1853-5; author reply 1853-5. PubMed ID: 16642596
    [No Abstract]   [Full Text] [Related]  

  • 9. Has acetylcysteine use changed the incidence of contrast nephropathy in hospitalized patients? A before-after study.
    Shah SJ; Hsu CY
    Am J Med; 2004 Dec; 117(12):948-52. PubMed ID: 15629734
    [No Abstract]   [Full Text] [Related]  

  • 10. Investigating the volume status before contrast nephropathy studies.
    Toprak O; Cirit M
    Nephrol Dial Transplant; 2005 Feb; 20(2):464; author reply 464-6. PubMed ID: 15673702
    [No Abstract]   [Full Text] [Related]  

  • 11. The value of hydration and acetylcysteine in the prevention of contrast-induced nephropathy: a potentially catastrophic complication of the percutaneous coronary interventions.
    Iyisoy A; Celik T; Yuksel UC; Bugan B; Isik E
    Int J Cardiol; 2009 May; 134(3):431-3; author reply 434. PubMed ID: 18501445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy?
    Gonzales DA; Star RA; Kern SJ; Natanson C; Danner RL
    Ann Intern Med; 2008 Aug; 149(3):213-4; author reply 215-6. PubMed ID: 18678852
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy?
    Berwanger O
    Ann Intern Med; 2008 Aug; 149(3):215; author reply 215-6. PubMed ID: 18678855
    [No Abstract]   [Full Text] [Related]  

  • 14. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy?
    Ferrante G; Locca D; Barlis P
    Ann Intern Med; 2008 Aug; 149(3):214-5; author reply 215-6. PubMed ID: 18678854
    [No Abstract]   [Full Text] [Related]  

  • 15. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy?
    Trivedi H
    Ann Intern Med; 2008 Aug; 149(3):213; author reply 215-6. PubMed ID: 18678853
    [No Abstract]   [Full Text] [Related]  

  • 16. N-acetylcysteine in preventing contrast-induced nephropathy. To give, or not to give: that is the question.
    Mehran R; Caixeta A
    Rev Esp Cardiol; 2010 Jan; 63(1):9-11. PubMed ID: 20089220
    [No Abstract]   [Full Text] [Related]  

  • 17. The third strike.
    Brinker JA
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):284-5. PubMed ID: 12410498
    [No Abstract]   [Full Text] [Related]  

  • 18. N-acetylcysteine and contrast-induced nephropathy.
    Wolak A; Cafri C; Zahger D
    N Engl J Med; 2006 Oct; 355(14):1498; author reply 1499-500. PubMed ID: 17024739
    [No Abstract]   [Full Text] [Related]  

  • 19. Contrast-induced nephropathy: a clinical and evidence-based approach.
    Tepel M; Aspelin P; Lameire N
    Circulation; 2006 Apr; 113(14):1799-806. PubMed ID: 16606801
    [No Abstract]   [Full Text] [Related]  

  • 20. N-acetylcysteine and contrast-induced nephropathy.
    Balderramo DC
    N Engl J Med; 2006 Oct; 355(14):1498-9; author reply 1499-500. PubMed ID: 17024740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.